For pharmaceutical companies, looking for further exploration of small molecule therapy for PD. but just enough already with the palliatives, what we need is cell replacement therapy. It it terrible that DBS is the neuro's last words. In today's worlds of biochemical knowledge it is a shame that we are not ten years ahead on this.